ESMO 2024

New updates from the innovative I-SPY program

Therapy de-escalation and balancing individualized…

4-year update of Riboclib in EBC - can we avoid chemo?

Escalation, De-escalation and management of therapy:…

Registry data from France - no break in endocrine…

Survival data from WSG-TP-II

Endocrine therapy in triple-positive premenopausal…

Overall survival advantage for Pembrolizumab in early…

Survival benefit reported with Pembro

Physical exercise and oncological outcome

Evaluation of the patient collective under 40 years

Ribociclib in younger patients

4-year landmark data

Physical exercise and oncological outcome

T-DXD for everyone - what is the minimal threshold for…

New approaches to treat 1L patients mTNBC

Highlights of ESMO 2024

No benefit of Akt-inhibition in mTNBC

Brain imaging screening in MBC patients

PIK3CA is not a vaild pathway in triple-negative breast…

Akt-inhibition works with HR+ but not with mTNBC

TILs and overall survival in the shortHER trial

Keep the patients trained!

PIK3CA is not a vaild pathway in triple-negative breast…

TILs e sopravvivenza nello studio shortHER

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

New first choice treatment for patients with brain…

Outstanding efficacy of T-Dxd in CNS meastases

T-Dxd in patients with and without brain metastases

Her3-Dxd - new application area for ADCs

Primary results of DB-12

Soon no chemotherapy for triplenegative mBC

Study impression in HR+/HER2- mBC progressing after two…

ctDNA data and clinical efficacy of SG

HER3- DXd in the ICARUS Breast-01 study

T-Dxd in BrainMets

Primary systematic treatment of active brain metastases

Endocrine-based therapy in combination with dual…

Efficacy of T-Dxd in patients with brain metastasis

Optimization treatment with ADCs in endocrine therapy

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

Impressione dello studio nel carcinoma mammario…

Screening for brain metastases – what do doctors and…

Overview on the perioperative treatment landscape

Getting rid of it will save your life!

Significant CNS protection by osimertinib

ctDNA - a promising new biomarker in early lung cancer

Should we move away from adjuvant immunotherapy?

BR31: The first negative adjuvant study in resected…

Neoadjuvant vs. Perioperative

Durvalumab did not meet primary endpoint in CCTG BR.31…

Perioperative IO Therapy - adjuvant necessary?

Eliminarlo potrebbe salvarti la vita

Durvalumab non ha raggiunto l'endpoint primario nello…

Should we move away from adjuvant immunotherapy?

Pieces of evidence in the EGFR domain

Update on genetic alterations - ALK / ROS / KRAS / BRAF

Half of the dose - same activity: provocative findings…

Quality of life with Telisotuzumab in LUMINOSITY

Bispecific antibodies better than ADCs?

The next generation of ALK inhibitors

Early mechanisms of resistance from MARIPOSA

Second interim analysis of MARIPOSA-2

NVALT: 1st attempt to reduce dose of pembrolizumab and…

MARIPOSA - lower rate of MET amplification and EGFR…

Adding anti-LAG-3 doesn't seem to being worth it

NVL-655: a promising new ALK inhibitor

Survival Data with Amivantamab for EGFR Alteration

NVL-520 for ROS alteration - already best in class?

RELATIVITY-104: efficacy of anti immunotherapy

Optimizing the dose of immunotherapy

4th generation with ALK-alterations

Patterns of resistance in MARIPOSA trial

The next generation of ROS inhibitors

Two sometimes may be better than one!

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1…

Sustained OS at 2nd interim analysis in MARIPOSA-2

2 a volte sono meglio di uno

Optimizing the dose of immunotherapy

Patterns of resistance in MARIPOSA trial

RELATIVITY-104: efficacy of anti immunotherapy

NVALT: Première tentative pour réduire la dose de…

Quality of life with Telisotuzumab in LUMINOSITY

Aggiungere l'anti-LAG-3 non sembra valerne la pena

Second interim analysis of MARIPOSA-2

New standard of care in LS-SCLC

Is the radiologist redundant in mesothelioma RECIST…

Doublet therapy in prostate cancer: Practice changing…

Practice changing- Big Revival - Or just a Splish?…

New hormone therapy for mCRPC

We come in PEACE

Radium and enzalutamide in mCRPC - final results

Was it a splash or was it a splish?

Immunotherapy for prostate cancer

Darolutamide in mHSPC

Radium223 Prior to Docetaxel Improves Quality of Life…

Metformin in mHSPC

Molecular analysis from PEACE-1

New PSMA-ligand

Not a Patch on ADT?

Radium-223 an option again?

PSMA-radioligand - the first study of its kind

Did CONTACT make any contact?

LuPSMA moves UpFront

New PSMA-ligand

Radium and enzalutamide in mCRPC - final results

Molecular analysis from PEACE-1

Where is the right place for HIF inhibitors in advanced…

Microbiome transplantation in RCC – how to tailor this…

Establishing ICI as standard of care in RCC

Glycoproteins as Predictive Biomarkers for Nivolumab…

Treating nccRCC - Nivo/Ipi as a new potential option

The role of sequencing therapy in RCC

HIF-2a inhibitors are on their way

TKI monotherapy remains standard in 2ndL

SUNNIFORECAST - rain or shine?

Sequencing checkpoint inhibitors - the story is over

FMT in a novel setting

CPI - modification / prediction - fact or fantasy?

IO therapy is standard for nccRCC

My view on SUNNIFORECAST

Stool transplantation is the shit

mRCC ≥ 1L? News on intensification?

Immunotherapy for nccRCC

Updated survival results

Ipi-Nivo in nccRCC

New SOC for non-cc-RCC?

Sequencing checkpoint inhibitors - the story is over

Se abre una nueva vía de tratamiento en el cáncer de…

Chemo + IO in the perioperative setting - new standard…

Biomarkers in Bladder cancer - the road to…

New data on ADCs in bladder cancer

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality…

Pretzel therapy for superficial UC

New standard: perioperative MIBC-NIAGARA

A new way to give chemo for patients who are ineligible…

EV + Pembro is broadly effective

mUC - new ADC's?

Practice changing new data in Bladder cancer at ESMO24

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

NIAGARA sets new standard

Is intravesical therapy as easy as baking a pretzel?

A new way to give chemo for patients who are ineligible…

Practice changing new data in Bladder cancer at ESMO24